Current Liabilities
Other Commercial Liabilities
Moderna Other Commercial Liabilities increased by 38.0% to $1.91B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 91.0%, from $1.00B to $1.91B. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows an upward trend with a 24.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2017
Last reportedQ1 2026May 1, 2026
Metric ID:
commercial_liabilities_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $848.00M | $1.08B | $1.47B | $1.61B | $1.78B | $1.86B | $2.10B | $1.61B | $1.49B | $2.22B | $1.80B | $1.40B | $1.33B | $1.38B | $1.43B | $1.00B | $987.00M | $1.18B | $1.39B | $1.91B |
| QoQ Change | — | +26.9% | +36.8% | +9.2% | +10.7% | +4.3% | +13.2% | -23.2% | -7.6% | +49.3% | -19.2% | -22.4% | -4.5% | +3.2% | +3.7% | -29.9% | -1.4% | +19.4% | +17.7% | +38.0% |
| YoY Change | — | — | — | — | +109.9% | +72.5% | +42.7% | +0.3% | -16.3% | +19.8% | -14.4% | -13.5% | -10.5% | -38.1% | -20.6% | -28.3% | -26.0% | -14.4% | -2.9% | +91.0% |
Range$848.00M – $2.22B
CAGR+18.7%
Avg YoY Growth+9.5%
Median YoY Growth-12.0%
Current Streak3 quarters growth
Other Commercial Liabilities at Other Companies
Frequently Asked Questions
- What is Moderna's other commercial liabilities?
- Moderna (MRNA) reported other commercial liabilities of $1.91B in Q1 2026.
- How has Moderna's other commercial liabilities changed year-over-year?
- Moderna's other commercial liabilities increased by 91.0% year-over-year, from $1.00B to $1.91B.
- What is the long-term trend for Moderna's other commercial liabilities?
- Over 5 years (2020 to 2025), Moderna's other commercial liabilities has grown at a 24.1% compound annual growth rate (CAGR), from $470.00M to $1.39B.